Abteilung für Haematologie und internistische Onkologie Trials

Abteilung für Haematologie und internistische Onkologie	Welcome, Profile Billing Logout

Abteilung für Haematologie und internistische Onkologie

Welcome, Profile Billing Logout

4 Trials

9 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Franke, Georg-Nikolaus

IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting

210

Europe

MC0518, BAT

medac GmbH

Steroid-refractory Acute Graft-versus-host Disease

08/27

08/30

OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting

225

Europe, Canada, Japan, US, RoW

Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)

F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi

Invasive Aspergillosis

09/25

11/26

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/27

11/28

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Recruiting

440

Europe, RoW

Allogeneic Stem Cell Transplantation

Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG)

Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes

11/22

11/24

MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting

Europe, US, RoW

GB2064

Galecto Biotech AB, OPIS s.r.l

Myelofibrosis

12/23

06/26

NCT06648889: Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Recruiting

Europe

Isatuximab, Bortezomib

Goethe University, Sanofi

T-ALL

02/28

08/28

BlastCrisis, NCT03869502: European CML Blast Crisis Register

Recruiting

N/A

250

Europe, RoW

University of Jena

Chronic Myeloid Leukemia in Myeloid Blast Crisis

06/24

TAK-620-5010, NCT06615921: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

Recruiting

N/A

150

Europe, RoW

No Intervention

Takeda

Cytomegalovirus (CMV)

04/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Franke, Georg-Nikolaus

IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting

210

Europe

MC0518, BAT

medac GmbH

Steroid-refractory Acute Graft-versus-host Disease

08/27

08/30

OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting

225

Europe, Canada, Japan, US, RoW

Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)

F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi

Invasive Aspergillosis

09/25

11/26

MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting

249

Europe, Japan, US, RoW

mocravimod

Priothera SAS, Priothera S.A.S.

Adult Acute Myeloid Leukemia

11/27

11/28

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Recruiting

440

Europe, RoW

Allogeneic Stem Cell Transplantation

Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG)

Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes

11/22

11/24

MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting

Europe, US, RoW

GB2064

Galecto Biotech AB, OPIS s.r.l

Myelofibrosis

12/23

06/26

NCT06648889: Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Recruiting

Europe

Isatuximab, Bortezomib

Goethe University, Sanofi

T-ALL

02/28

08/28

BlastCrisis, NCT03869502: European CML Blast Crisis Register

Recruiting

N/A

250

Europe, RoW

University of Jena

Chronic Myeloid Leukemia in Myeloid Blast Crisis

06/24

TAK-620-5010, NCT06615921: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

Recruiting

N/A

150

Europe, RoW

No Intervention

Takeda

Cytomegalovirus (CMV)

04/25

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites